The trial, which will start enrollment for the CAD106 dosing arm in late 2015, will be a decisive turning point in pin-pointing the onset of AD and could possibly shift the approaches being used in Alzheimer’s research in favor of tau inhibition mechanisms if the trials end in failure. The gene discussed is MAPT; the disease is Alzheimer disease.